Nothing Special   »   [go: up one dir, main page]

AR089122A1 - Formulaciones orales para tratar la sobrecarga de metales - Google Patents

Formulaciones orales para tratar la sobrecarga de metales

Info

Publication number
AR089122A1
AR089122A1 ARP120104611A ARP120104611A AR089122A1 AR 089122 A1 AR089122 A1 AR 089122A1 AR P120104611 A ARP120104611 A AR P120104611A AR P120104611 A ARP120104611 A AR P120104611A AR 089122 A1 AR089122 A1 AR 089122A1
Authority
AR
Argentina
Prior art keywords
hydroxy
integer
hydrogen
independently selected
alkoxy
Prior art date
Application number
ARP120104611A
Other languages
English (en)
Original Assignee
Ferrokin Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48574916&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR089122(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferrokin Biosciences Inc filed Critical Ferrokin Biosciences Inc
Publication of AR089122A1 publication Critical patent/AR089122A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D277/12—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Formulaciones orales eficaces basadas en análogos de desazadesferritiocin-poliéter (DADFT-PE), sus sales y polimorfos, así como también su aplicación para el tratamiento de la sobrecarga de metal, en particular, la sobrecarga férrica, y enfermedades, trastornos y afecciones asociados. Reivindicación 1: Una formulación oral que comprende un compuesto de fórmula (1) en una cantidad eficaz para tratar la sobrecarga de metal y un excipiente farmacéuticamente aceptable, donde: R¹, R², R³, R⁴, y R⁵ se seleccionan independientemente entre hidrógeno, hidroxi, alquilo, arilalquilo, alcoxi, y CH₃O((CH₂)ₙ-O)ₘ-, cualquiera de los cuales puede estar opcionalmente sustituido; R⁶, R⁷, y R⁸ se seleccionan independientemente entre hidrógeno, halógeno, hidroxi, alquilo inferior, y alcoxi inferior; m es un número entero de 0 a 8; y n es un número entero de 0 a 8; o su sal o polimorfo. Reivindicación 38: Una forma de dosificación sólida que comprende un compuesto de fórmula (1) y un excipiente farmacéuticamente aceptable, donde la forma de dosificación sólida se caracteriza por una velocidad de disolución que da como resultado más del 50% del compuesto de fórmula (1) se disuelve en solución dentro de los 30 minutos en un ensayo de disolución conducido según un protocolo estándar de la USP, la Farmacopea Europea o la Farmacopea Británica; donde: R¹, R², R³, R⁴, y R⁵ se seleccionan independientemente entre hidrógeno, hidroxi, alquilo, arilalquilo, alcoxi, y CH₃O((CH₂)ₙ-O)ₘ-, cualquiera de los cuales puede estar opcionalmente sustituido; R⁶, R⁷, y R⁸ se seleccionan independientemente entre hidrógeno, halógeno, hidroxi, alquilo inferior, y alcoxi inferior; m es un número entero de 0 a 8; y n es un número entero de 0 a 8; o su sal o polimorfo.
ARP120104611A 2011-12-09 2012-12-07 Formulaciones orales para tratar la sobrecarga de metales AR089122A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161568914P 2011-12-09 2011-12-09
US201161568890P 2011-12-09 2011-12-09

Publications (1)

Publication Number Publication Date
AR089122A1 true AR089122A1 (es) 2014-07-30

Family

ID=48574916

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120104611A AR089122A1 (es) 2011-12-09 2012-12-07 Formulaciones orales para tratar la sobrecarga de metales

Country Status (9)

Country Link
US (1) US8993606B2 (es)
EP (1) EP2787994A4 (es)
JP (1) JP2015500294A (es)
AR (1) AR089122A1 (es)
AU (1) AU2012347595A1 (es)
BR (1) BR112014013985A2 (es)
CA (1) CA2857990A1 (es)
TW (1) TW201338777A (es)
WO (1) WO2013086312A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102111176B1 (ko) 2011-12-16 2020-05-15 유니버시티 오브 플로리다 리서치 파운데이션, 인코포레이티드 4'-데스페리티오신 유사체의 용도
EP2970162A1 (en) 2013-03-15 2016-01-20 Ferrokin Biosciences, Inc. Polymorph forms of desazadesferrithiocin analogs
EP3071201A4 (en) * 2013-11-22 2017-04-26 University of Florida Research Foundation, Inc. Desferrithiocin analogs and uses thereof
KR20170140306A (ko) 2015-04-27 2017-12-20 유니버시티 오브 플로리다 리서치 파운데이션, 인코포레이티드 대사적으로 프로그램화된 금속 킬레이트화제 및 그의 용도
WO2018104130A1 (en) 2016-12-07 2018-06-14 Lumileds Holding B.V. Flash light emitter with remote communication function
US20220273634A1 (en) 2019-07-19 2022-09-01 Vifor (International) Ag Ferroportin-Inhibitors For The Use In The Treatment Of Transfusion-Dependent Beta-Thalassemia (TDT)
WO2022157185A1 (en) 2021-01-20 2022-07-28 Vifor (International) Ag Ferroportin-inhibitors for the use in the treatment of myelodysplastic syndromes (mds)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2603385C (en) 2005-04-04 2014-07-15 University Of Florida Research Foundation, Inc. Desferrithiocin polyether analogues and uses thereof for treating metal overload, oxidative stress, and neoplastic and preneoplastic conditions
US8067451B2 (en) * 2006-07-18 2011-11-29 Horizon Pharma Usa, Inc. Methods and medicaments for administration of ibuprofen
CA2680592C (en) 2007-03-15 2016-07-05 University Of Florida Research Foundation, Inc. Desferrithiocin polyether analogues and uses thereof in treating pathological conditions
NZ590302A (en) 2008-07-14 2013-02-22 Ferrokin Biosciences Inc Novel salts and polymorphs of desazadesferrithiocin polyether analogues as metal chelation agents
CN102648189A (zh) 2009-07-27 2012-08-22 费罗金生物科学股份有限公司 作为金属螯合剂的脱氮杂去铁硫辛聚醚类似物的前药
AU2010290103B2 (en) 2009-08-25 2016-07-14 University Of Florida Research Foundation, Inc. Desferrithiocin polyether analogues and uses thereof
US9045440B2 (en) 2010-05-04 2015-06-02 Ferrokin Biosciences, Inc. Desazadesferrothiocin and desazadesferrothiocin polyether analogues as metal chelation agents

Also Published As

Publication number Publication date
EP2787994A1 (en) 2014-10-15
EP2787994A4 (en) 2015-08-26
US8993606B2 (en) 2015-03-31
AU2012347595A1 (en) 2014-06-26
WO2013086312A1 (en) 2013-06-13
CA2857990A1 (en) 2013-06-13
US20130225645A1 (en) 2013-08-29
JP2015500294A (ja) 2015-01-05
TW201338777A (zh) 2013-10-01
BR112014013985A2 (pt) 2017-06-13

Similar Documents

Publication Publication Date Title
AR089122A1 (es) Formulaciones orales para tratar la sobrecarga de metales
CU20150014A7 (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
CO2018013717A2 (es) Piridinas sustituidas como inhibidores de dnmt1
CO6470847A2 (es) Derivados amino-propiónicos sustituidos como inhibidores de neprilisina
CO6470846A2 (es) Derivados aminobut´ricos sustituidos como inhibidores de neprilisina
BR112016000909A8 (pt) derivados piperidinil indólicos, seus usos, e combinação e composição farmacêuticas
UY33606A (es) DERIVADOS DE PIRAZINA COMO BLOQUEADORES DE ENaC
BR112015000106A2 (pt) moduladores heterocíclicos de síntes de lipídio
NI201100158A (es) Formulaciones de 4 - amino - 2 - (2, 6 - dioxopiperidina - 3 - il) isoindolina - 1, 3 - diona
DOP2014000008A (es) 4-imidazopiridazina-1-il-benzamidas y 4-imidazotriazina-1-il-benzamidas como inhibidores de btk
PE20221914A1 (es) Compuestos de benzaldehido sustituidos y metodos para su uso en incrementar la oxigenacion del tejido
CL2020001097A1 (es) Derivados de piridincarbonilo y usos terapéuticos de los mismos como inhibidores de trpc6.
CO6541528A2 (es) Derivados de la cromenona
UY32582A (es) Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero
CO7280475A2 (es) Derivados de azaindol que actuan como inhibidores de pi3k
CO2019009423A2 (es) Inhibidores de mnk sustituidos con piperidina y métodos relacionados con los mismos
CR20150419A (es) Derivados sustituidos del ácido bisfenil butanóico fosfónico como inhibidores de la nep
DOP2024000039A (es) Derivados de quinolina como inhibidores de la integrina alfa4beta7
AR087915A1 (es) N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1
UY36123A (es) Derivados de carboxamida
CU20190042A7 (es) Compuestos derivados de naftiridinona
UY33745A (es) Derivados de difenilamina: usos, procedimiento de síntesis y composiciones farmacéuticas
AR120158A2 (es) Derivados de indol mono o di sustituidos como inhibidores de la replicación viral del dengue
EA201891027A1 (ru) Фармацевтическая композиция, содержащая производные индола, способ ее получения и применение
AR111416A2 (es) Compuesto terapéutico para el dolor y síntesis del compuesto

Legal Events

Date Code Title Description
FA Abandonment or withdrawal